^
    2d
    COATS-VEGF: Interest of Intravitreal Injections of Anti-VEGF as Initial and Adjuvant Treatment in Coats Disease (clinicaltrials.gov)
    P3, N=18, Terminated, Fondation Ophtalmologique Adolphe de Rothschild | N=30 --> 18 | Suspended --> Terminated; Study futility based on the interim analysis
    Enrollment change • Trial termination
    |
    Avastin (bevacizumab)
    2d
    A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=254, Active, not recruiting, Shanghai Henlius Biotech
    New P1 trial
    8d
    ILLUMINE: Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN (clinicaltrials.gov)
    P3, N=780, Not yet recruiting, Groupe Oncologie Radiotherapie Tete et Cou
    New P3 trial
    |
    Keytruda (pembrolizumab) • Yidafan (ivonescimab) • ligufalimab (AK117)
    10d
    Unlocking new horizons in oncology: ivonescimab's dual-target approach to anti-VEGF/PD-1(L1) therapy. (PubMed, Front Immunol)
    PD-1(L1)/VEGF BsAbs like ivonescimab represent a novel therapeutic strategy with potential for improved efficacy and mitigated toxicity compared to combination therapies. Ongoing trials will define broader applications.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    Yidafan (ivonescimab)
    14d
    GRACIE: Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma (clinicaltrials.gov)
    P2, N=88, Recruiting, UNICANCER | Not yet recruiting --> Recruiting
    Enrollment open
    |
    paclitaxel • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • Yidafan (ivonescimab)
    16d
    HARMONi-3: Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients (clinicaltrials.gov)
    P3, N=1600, Recruiting, Summit Therapeutics | N=1080 --> 1600 | Trial completion date: Dec 2028 --> Dec 2029 | Trial primary completion date: Dec 2027 --> Dec 2028
    Enrollment change • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Yidafan (ivonescimab)
    17d
    M-VIVA: Identification of Molecular Signals in Vitreous Humor Associated With Suboptimal Response to Vascular Endothelial Growth Factor (VEGF) Inhibition in Neovascular Age-related Macular Degeneration (nAMD) Within a Clinical Trial Setting (clinicaltrials.gov)
    P=N/A, N=117, Recruiting, Singapore National Eye Centre
    New trial
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8)
    |
    Lucentis (ranibizumab)
    17d
    SENIOR-HN: Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer (clinicaltrials.gov)
    P2, N=28, Recruiting, University of Michigan Rogel Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Yidafan (ivonescimab)
    18d
    A Study of Ivonescimab in First-Line ES-SCLC (clinicaltrials.gov)
    P2, N=180, Recruiting, Akeso
    New P2 trial
    |
    carboplatin • etoposide IV • Kaitanni (cadonilimab) • Yidafan (ivonescimab) • ligufalimab (AK117)
    18d
    Neoadjuvant Ivonescimab（AK112） Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=49, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New P2 trial
    |
    carboplatin • albumin-bound paclitaxel • Yidafan (ivonescimab)
    18d
    Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervical Cancer (clinicaltrials.gov)
    P2, N=42, Not yet recruiting, Women's Hospital School Of Medicine Zhejiang University
    New P2 trial
    |
    cisplatin • carboplatin • albumin-bound paclitaxel • Yidafan (ivonescimab)
    21d
    BiomarkerOCT: Evaluation of Serum- and OCT Biomarkers in Patients With DME Treated With Anti-VEGF or Dexamethasone Implant (clinicaltrials.gov)
    P=N/A, N=150, Recruiting, Vastra Gotaland Region | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8) • ICAM1 (Intercellular adhesion molecule 1)